Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.

Clicks: 359
ID: 67897
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #6 of 13 articles by views in american heart journal

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Rates and predictors of major bleeding in patients with peripheral artery disease (PAD) treated with antiplatelets have not been well studied. This post hoc analysis of EUCLID aimed to determine the incidence of major/minor bleeding, predictors of major bleeding, and risk of major adverse cardiovascular events (MACE) following major bleeding events.EUCLID, a multicenter randomized controlled trial of 13,885 patients with symptomatic PAD, compared ticagrelor with clopidogrel for the prevention of MACE. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. Baseline characteristics were used to develop a multivariable model to determine factors associated with TIMI major bleeding. The occurrence and timing of MACE relative to a first major bleeding event were determined.TIMI major bleeding occurred in 2.3% of participants overall (0.94 event/100 patient-years). There was no significant difference in major bleeding rates by treatment assignment. Factors associated with TIMI major bleeding included older age, geographic region, Rutherford class, and β-blocker use. Patients with TIMI major bleeding postrandomization had an increased risk of MACE (hazard ratio [HR] 4.46; 95% CI 3.40-5.84; P < .0001) compared with those without major bleeding; the association was strongest within 30 days after a bleeding event.In patients with symptomatic PAD, 0.94 major bleeding event/100 patient-years was observed and associated with older age, residing in North America, disease severity, and β-blocker use. Patients who had a major bleeding event were significantly more likely to experience MACE, especially within the first 30 days, when compared with patients who did not have major bleeding.
Reference Key
ward2019majoramerican Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ward, Rachael;Huang, Zhen;Rockhold, Frank W;Baumgartner, Iris;Berger, Jeffrey S;Blomster, Juuso I;Fowkes, F Gerry R;Katona, Brian G;Mahaffey, Kenneth W;Norgren, Lars;Vemulapalli, Sreekanth;Povsic, Thomas J;Mehta, Rajendra;Hiatt, William R;Patel, Manesh R;Jones, W Schuyler;
Journal american heart journal
Year 2019
DOI
S0002-8703(19)30308-4
URL
Keywords
therapeutic endovascular procedures cerebrovascular disorders adf = active device fixation ai = artificial intelligence cca = common carotid artery ica = internal carotid artery pci = percutaneous coronary intervention pvi = peripheral vascular intervention minimally invasive surgical procedures robotic surgical procedures vascular disorders

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.